Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Ventilation 50% ICU admission 50% NIV 48% Fiore et al. Vitamin D for COVID-19 LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 116 patients in Italy Lower mortality (p=0.015) and progression (p=0.042) Fiore et al., Healthcare, doi:10.3390/healthcare10050956 Favors vitamin D Favors control
Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study
Fiore et al., Healthcare, doi:10.3390/healthcare10050956
Fiore et al., Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric.., Healthcare, doi:10.3390/healthcare10050956
May 2022   Source   PDF  
  All Studies   Meta
Retrospective 116 patients with D levels < 30ng/mL, 58 treated with vitamin D 100,000IU daily for two days, and 58 matched controls, showing significantly lower mortality with treatment.
risk of death, 92.7% lower, RR 0.07, p = 0.01, treatment 3 of 58 (5.2%), control 11 of 58 (19.0%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
NIV, 47.8% lower, RR 0.52, p = 0.04, treatment 12 of 58 (20.7%), control 23 of 58 (39.7%), NNT 5.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fiore et al., 22 May 2022, retrospective, matched cohort, Italy, peer-reviewed, mean age 62.5, 10 authors, dosage 100,000IU days 1-2.
Contact: (corresponding author),,,,,,,,,
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: healthcare Article Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study Vito Fiore 1, * , Andrea De Vito 1 , Paola Bagella 1 , Elija Princic 1 , Anna Antonella Mariani 1 , Lucia Denti 1 , Alessandro Giuseppe Fois 2 , Giordano Madeddu 1 , Sergio Babudieri 1 and Ivana Maida 1 1 2 * Infectious and Tropical Diseases Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy; (A.D.V.); (P.B.); (E.P.); (A.A.M.); (L.D.); (G.M.); (S.B.); (I.M.) Unit of Respiratory Diseases, University Hospital Sassari (AOU), 07100 Sassari, Italy; Correspondence: Academic Editor: Marina Sartini Abstract: Objectives: Our study aimed to evaluate the usefulness of Vitamin D3 (VitD3) among patients hospitalized for COVID-19. The primary endpoint was to evaluate the difference in survival rates between patients receiving and not VitD3. The secondary endpoints were to evaluate clinical outcomes, such as needing non-invasive ventilation (NIV), ICU transfer, and laboratory findings (inflammatory parameters). Methods: We conducted a retrospective, monocentric matched-cohort study, including patients attending our ward for COVID-19. Patients were divided into two groups depending on VitD3 administration (Group A) or not (Group B) among patients with low VitD levels (defined as blood levels < 30 ng/mL), which depended on physicians’ judgment. Our internal protocol provides VitD3 100,000 UI/daily for two days. Findings: 58 patients were included in Group A, and 58 in Group B. Patients were matched for age, sex, comorbidities, COVID-19-related symptoms, PaO2/FiO2 ratio, blood exams, and medical treatments. Regarding the principal endpoint, there was a statistically significant difference between the two groups in survival rates [Group A vs. Group B = 3 vs. 11 (p = 0.042)]. When considering secondary endpoints, Group A patients were less likely to undergo NIV [Group A vs. Group B = 12 vs. 23 (p = 0.026)] and showed an improvement in almost all inflammatory parameters. Conclusions: The link between VitD3 deficiency and the clinical course of COVID-19 during hospitalization suggests that VitD3 level is a useful prognostic marker. Considering the safety of supplementation and the low cost, VitD3 replacement should be considered among SARS-CoV-2 infected patients needing hospitalization. Received: 28 April 2022 Keywords: COVID-19; vitamin D3 supplement; SARS-CoV-2; matched cohort Citation: Fiore, V.; De Vito, A.; Bagella, P.; Princic, E.; Mariani, A.A.; Denti, L.; Fois, A.G.; Madeddu, G.; Babudieri, S.; Maida, I. Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study. Healthcare 2022, 10, 956. 10.3390/healthcare10050956 Accepted: 19 May 2022 Published: 22 May 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop